Dronabinol for Agitation in Dementia Crossover Trial

NCT ID: NCT05612711

Last Updated: 2024-07-05

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-30
• Study Completion Date: 2026-11-30

Brief Summary

The goal of this clinical trial is to study the effects of dronabinol in US Veterans with agitation related to moderate to severe dementia. The main goals of the study are:

• To evaluate the efficacy of dronabinol for the treatment of agitation in moderate to severe dementia compared to placebo
• To evaluate the safety of dronabinol in the treatment of agitation in moderate to severe dementia compared to placebo

Fifty (50) subjects will be given either dronabinol or placebo for 8 weeks. All subjects will then undergo a "washout" phase for 3 weeks, followed by the crossover intervention (i.e. subjects who received placebo during the first phase will receive dronabinol during the second phase, and vice versa). Thus, all participants will be taking dronabinol at some point during the study. During the study, subjects will undergo evaluations for:

• Agitation
• Cognitive changes
• Physical changes (i.e. labs, ekg, physical exam)

Detailed Description

The investigators will conduct a phase IIa study to evaluate the efficacy and safety of dronabinol in the treatment of agitation related to dementia in the US Veteran population.

Specific Aim 1 - To evaluate the efficacy of dronabinol (target dose 5 mg bid) for the treatment of agitation in dementia.

Hypothesis: Dronabinol improves clinically significant agitation in moderate to severe dementia. Approach: The investigators will conduct a 6-week, double-blind, placebo-controlled, crossover, exploratory study of 50 Veterans suffering from moderate to severe dementia and clinically significant agitation with the Cohen Mansfield Agitation Inventory (CMAI) total score as the main outcome measure. Impact: The potential benefit of dronabinol in agitation will be evaluated.

Specific Aim 2 - To evaluate the safety of dronabinol in the treatment of agitation in moderate to severe dementia.

Hypothesis: Dronabinol is safe for the treatment of agitation in moderate to severe dementia. Approach: Outcomes of safety monitoring are to be measured by physical examination, vital signs with weight, adverse event reports, electrocardiogram, safety labs including complete metabolic panel (CMP), complete blood count (CBC), urinalysis (UA), and treatment compliance. Impact: The potential adverse effects of the 5 mg dose of dronabinol will be evaluated.

Exploratory Aims - The investigators will also evaluate the effect of dronabinol on neuropsychiatric symptoms, caregiver distress, cognition, weight, nutritional status, pain, and inflammation.

Conditions

Dementia Moderate; Dementia Severe; Agitation,Psychomotor; Behavioral Symptoms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Dronabinol First

Participants will take Dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week. They will then undergo a 3-week washout period, followed by placebo capsules twice daily for 8 weeks.

Group Type: EXPERIMENTAL

Dronabinol

Intervention Type: DRUG

All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.

Placebo First

Participants will take matching placebo capsules twice daily for 8 weeks, followed by a three week washout period. They will then begin taking dronabinol 2.5 mg capsules twice daily for 1 week, followed by dronabinol 5 mg twice daily for 6 weeks, followed by dronabinol 2.5 mg twice daily for 1 week.

Group Type: EXPERIMENTAL

Dronabinol

Intervention Type: DRUG

All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.

Interventions

Dronabinol

All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.

Intervention Type: DRUG

Other Intervention Names

Marinol

Eligibility Criteria

Inclusion Criteria

• US Veteran who is not pregnant or unable to become pregnant
• Diagnosis of Major Neurocognitive Disorder (aka dementia) of any type
• Functional Assessment Staging Test (FAST) score of 5 or higher
• Presence of clinically significant agitation and/or irritability with an NPI subscale score greater than or equal to 4
• If treated with cholinesterase inhibitors or memantine, dosage must be stable for 3 months, or if discontinued they may enroll after 1 month
• Must be able to swallow capsules
• Must meet International Psychogeriatric Association's provisional definition of agitation in dementia.
• Must have decisional capacity to sign informed consent or have a legally authorized representative available to provide consent
• Must have an available study partner who spends at least 10 hours per week with the subject.

Exclusion Criteria

• Psychotropic medication changes (i.e. concomitant antidepressants, antipsychotics) less than 1 month prior to study randomization
• Contraindications to dronabinol (hypersensitivity or allergy to any cannabinoid or sesame oil)
• Use of cannabinoids (including over the counter products such as "CBD" or medical cannabis) or other illicit drugs in the past 3 months
• History of psychotic symptoms due to another psychiatric illness other than dementia int he past 2 years.
• Unstable current psychiatric disorder or neurologic condition (i.e. unstable depression, bipolar disorder, epilepsy, etc.) other than agitation or psychosis due to dementia.
• Suicidal ideations in the past 3 months or attempts in the past year
• Clinically significant delusions and/or hallucinations which are considered by the PI's to be a contraindication for dronabinol use
• Taking 1 or more medications which in the judgement of the PI's can be contraindicated with the use of dronabinol
• Unstable or uncontrolled medical conditions including cardiovascular system issues (i.e. angina, cardiac arrhythmias, recurrent syncope, hypertension, etc) as judged by the PI's.

• Minimum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

JHSPH Center for Clinical Trials

OTHER

Sponsor Role: collaborator

Ralph H. Johnson VA Medical Center

FED

Sponsor Role: lead

Responsible Party

Jacobo Mintzer, MD

Professor, Geriatric Psychaitrist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jacobo E Mintzer, MD

Role: PRINCIPAL_INVESTIGATOR

Ralph H. Johnson VA Healthcare System

Jessica E Broadway, MD

Role: PRINCIPAL_INVESTIGATOR

Ralph H. Johnson VA Healthcare System

Locations

Ralph H. Johnson VA Health Care System

Charleston, South Carolina, United States

Countries

United States

Other Identifiers

1I01CX002671

Identifier Type: -

Identifier Source: org_study_id